Home Ingredients D-Serine
CognitiveMood & Mental Health

D-Serine

Evidence Level
Limited
3 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

D-serine is an amino acid that acts as a co-agonist at NMDA receptors in the brain, helping regulate a signaling system central to learning, memory, and mood. Because of this role in synaptic plasticity, it is studied, largely in research settings, for cognitive and mood-related support, though it remains mostly investigational as a supplement. Its use is not well standardized, so dosing should be approached cautiously. While low amounts are generally tolerated, high doses have raised kidney-safety questions in research, so caution is warranted, and those with kidney concerns or on medication should consult a doctor before considering it.

Studied Dose Schizophrenia 30 mg/kg/day (~2–2.5 g/day adult), up to 120 mg/kg/day; multicenter trials 2 g/day. Investigational only.
Active Compound D-serine (D-isomer of serine).

Benefits

Schizophrenia Negative Symptoms — Mixed Results

Early trials suggested adjunctive D-serine added to antipsychotics improved negative symptoms (apathy, social withdrawal, blunted affect) and some cognitive measures. A larger multicenter RCT (16 weeks) did not replicate these benefits at 2 g/day, possibly due to lower achieved doses than prior studies.

Supported by Trial 1, Trial 2

Potential Cognitive Effects in Schizophrenia

Some studies report improvements in Wisconsin Card Sorting Test and other neurocognitive measures with D-serine adjunctive therapy. Effects appear dose-dependent — higher doses (60-120 mg/kg/day) produced more consistent cognitive benefits than the 2 g/day dose used in some negative trials.

Supported by Trial 2, Trial 1

NMDA Receptor Modulation

D-serine is the dominant endogenous co-agonist at the glycine site of NMDA receptors in adult forebrain. Reduced D-serine levels are implicated in NMDA hypofunction theories of schizophrenia and cognitive aging. This biological rationale drives ongoing research.

Supported by Trial 2, Trial 3

Investigational for Other Conditions

D-serine has been investigated for major depression, OCD, PTSD, and Alzheimer's disease — all based on the NMDA modulation hypothesis. Evidence in these conditions is preliminary and limited to small trials with mixed outcomes.

Supported by Trial 3

Mechanism of action

1

NMDA Receptor Glycine Site Co-Agonist

D-Serine binds the glycine modulatory site of the NMDA glutamate receptor, which must be occupied for the receptor to activate when glutamate binds. D-Serine is the predominant endogenous agonist at this site in mature forebrain (whereas glycine dominates in spinal cord/brainstem).

2

Synaptic Plasticity Enhancement

Through NMDA receptor potentiation, D-serine supports long-term potentiation (LTP) — the cellular basis of learning and memory. This rationale underlies its investigation as a cognitive enhancer in schizophrenia and as an adjunct to cognitive remediation therapy.

3

Glutamatergic-Dopaminergic Balance

Schizophrenia is increasingly understood as involving NMDA receptor hypofunction (in addition to classic dopaminergic theories). D-serine's mechanism aims to restore normal glutamatergic tone, indirectly modulating dopaminergic signaling abnormalities.

4

Endogenous Synthesis from L-Serine

D-serine is synthesized in the brain from L-serine by serine racemase, primarily in astrocytes and neurons. It's degraded by D-amino acid oxidase (DAAO). Inhibitors of DAAO are being explored as alternative or complementary therapeutic approaches.

Clinical trials

1
Multicenter D-Serine Clinical Trial in Schizophrenia (Negative Result)

16-week, multicenter, double-blind, randomized, placebo-controlled trial of D-serine 2 g/day as adjunctive treatment to antipsychotics. Subjects had DSM-IV schizophrenia or schizoaffective disorder with persistent negative symptoms. Primary outcomes: SANS and MATRICS cognitive battery. NCT00138775. (Weiser, Heresco-Levy, Davidson, Javitt, Werbeloff, Gershon, Abramovich, Amital, Doron, Konas, Levkovitz, Liba, Teitelbaum, Mashiach, J Clin Psychiatry)

195 patients with schizophrenia/schizoaffective disorder. 16-week intervention.

No significant difference between D-serine and placebo. Improvement on SANS was 11.4% for D-serine vs. 14.8% for placebo (p=0.32); MATRICS improvements were similar. D-serine was well-tolerated. Authors attribute the negative result partly to large placebo response and lower achieved doses than prior positive studies — suggesting higher doses may be needed.

2
D-Serine Adjunctive Treatment in Schizophrenia (Foundational Clinical Trial)

6-week double-blind, placebo-controlled trial of D-serine (30 mg/kg/day) added to stable antipsychotic regimens in Taiwanese schizophrenic patients. Outcomes: clinical efficacy, side effects, serum amino acid levels, Wisconsin Card Sorting Test. (Tsai, Yang, Chung, Lange, Biol Psychiatry)

31 patients enrolled, 28 completed. 6-week intervention.

D-Serine treatment significantly improved positive, negative, and cognitive symptoms vs. placebo, with measurable improvements on Wisconsin Card Sorting Test. This was the foundational positive trial that established D-serine as a candidate adjunct for schizophrenia.

3
D-Serine Cognitive Retraining Clinical Trial

Phase 3 randomized, triple-blind, placebo-controlled trial of D-serine (30 mg/kg) combined with cognitive retraining therapy in schizophrenia/schizoaffective disorder. 12-week intervention. (Yale University, completed 2010)

104 patients with schizophrenia or schizoaffective disorder receiving antipsychotic medication.

Investigated whether D-serine enhances cognitive remediation outcomes via increased NMDA receptor function. Detailed published outcomes are mixed — augmentation effects with cognitive training have been suggested but with substantial inter-trial variability.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated in published clinical trials at doses up to 30-60 mg/kg/day.
Mild GI upset (nausea, diarrhea) reported by some participants.
Potential nephrotoxicity at very high doses: animal studies show D-serine can damage kidney proximal tubules; human safety at chronic high doses (>120 mg/kg/day) is not well-characterized.
Headache and sedation reported in some trials.
Should not be self-administered as a consumer supplement — investigational use only under medical supervision.
Pregnancy and lactation: no data; avoid.

Important Drug interactions

Antipsychotics (clozapine, olanzapine, risperidone, etc.): D-serine has been studied as an adjunct, not a replacement. Co-administration is the studied paradigm.
NMDA antagonists (ketamine, memantine, dextromethorphan, PCP): D-serine acts at the same receptor complex; theoretical interaction.
D-amino acid oxidase inhibitors (sodium benzoate, investigational drugs): may potentiate D-serine effects.
Lamotrigine and other glutamate modulators: theoretical interaction; clinical relevance unclear.

More Cognitive Ingredients

Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Cognitive
Longvida® Optimized Curcumin (Verdure Sciences)
Longvida® is a patented curcumin extract developed by Verdure Sciences using SLCP™ (Solid…
Cognitive
CurQfen® (Curcumin-Fenugreek FenuMat — Akay Bioactives)
CurQfen® is a patented curcumin complex from Curcuma longa rhizomes formulated with FENUMA…
Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an adaptogenic herb from Ayurvedic tradition, widely u…

Explore Other Ingredients

Cognitive
Bacopa Monnieri
Bacopa monnieri (Brahmi) is a cornerstone herb in Ayurvedic medicine with over 3,000 years…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…
Cognitive
Citicoline
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine bios…

Frequently asked questions about D-Serine

What is D-serine used for?

D-serine is an amino acid that acts as a co-agonist at NMDA receptors in the brain, helping regulate a key system involved in learning, memory, and mood. It is studied (often in research settings) for cognitive and mood-related support.

What does D-serine do in the brain?

By supporting NMDA-receptor signaling, D-serine is involved in synaptic plasticity, the basis of learning and memory. Research has explored it for cognition and certain mental-health conditions, though it remains largely investigational as a supplement.

How much D-serine should I take?

Research doses vary widely and some are quite high under medical supervision. As a supplement its use is not well standardized, so follow product labeling cautiously and ideally consult a knowledgeable clinician.

Is D-serine safe?

At low amounts it is generally tolerated, but high doses have raised kidney-safety questions in research. Because human supplement data is limited, use caution, avoid high doses, and check with a doctor, especially with kidney concerns.

What is D-Serine?

D-serine is an amino acid that acts as a co-agonist at NMDA receptors in the brain, helping regulate a signaling system central to learning, memory, and mood. Because of this role in synaptic plasticity, it is studied, largely in research settings, for cognitive and mood-related support, though it remains mostly invest…

What is the recommended dosage of D-Serine?

The clinically studied dose is Schizophrenia 30 mg/kg/day (~2–2.5 g/day adult), up to 120 mg/kg/day; multicenter trials 2 g/day. Investigational only. Always follow the product label and check with a healthcare provider for personal advice.

Is D-Serine safe, and does it have side effects?

For most healthy adults, D-Serine is well tolerated at studied doses. Reported effects can include: Generally well-tolerated in published clinical trials at doses up to 30-60 mg/kg/day. Mild GI upset (nausea, diarrhea) reported by some participants. It may also interact with some medications. D-Serine is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does D-Serine interact with any medications?

Possible interactions include: Antipsychotics (clozapine, olanzapine, risperidone, etc.): D-serine has been studied as an adjunct, not a replacement. Co-administration is the studied paradigm. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for D-Serine?

NutraSmarts rates the evidence for D-Serine as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia Biological Psychiatry. 2005;57(6):577-85. doi:10.1016/j.biopsych.2004.12.037.PubMedUsed to support: Double-blind placebo-controlled crossover RCT (n=39) demonstrating that D-serine 30 mg/kg/day added to atypical antipsychotics produced significant improvements in negative, positive, cognitive, and depression symptoms in treatment-refractory schizophrenia, with good tolerability. Supports the schizophrenia negative symptoms and potential cognitive effects benefits via NMDA receptor co-agonism.
  2. Mark Weiser, Uriel Heresco-Levy, Michael Davidson, Daniel C Javitt, Nomi Werbeloff, Ari A Gershon, Yehuda Abramovich, Daniela Amital, Adiel Doron, Shai Konas, Yehiel Levkovitz, David Liba, Alexander Teitelbaum, Mordechai Mashiach, Yosef Zimmerman A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia Journal of Clinical Psychiatry. 2012;73(6):e728-34. doi:10.4088/JCP.11m07031.PubMedUsed to support: Large multicenter RCT (n=195) testing low-dose D-serine add-on for schizophrenia; found no significant difference from placebo (11.4% vs 14.8% negative symptom improvement), with authors noting a large placebo response and recommending higher doses. Included for balanced reporting of the mixed evidence for D-serine in schizophrenia negative symptoms — the primary negative result in this evidence tier.
  3. Herman Wolosker, Darrick T Balu D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders Translational Psychiatry. 2020;10(1):184. doi:10.1038/s41398-020-00870-x.PubMedUsed to support: Mechanistic review establishing D-serine as a required co-agonist at the glycine modulatory site of NMDA receptors, essential for fear extinction and anxiety processing. Describes the serine shuttle between astrocytes and neurons and implications for targeting D-serine availability for cognitive and mood disorders. Supports the NMDA receptor modulation mechanism and investigational cognitive/anxiety effects of D-serine.